National Expert Program & Educational Series

You’re invited! The Beyfortus (nirsevimab-alip) 50 mg and 100 mg Injection Expert Series

The Beyfortus Expert Series is an ongoing educational series where you can learn more about Beyfortus from national experts.

RSV image

Join the RSV experts for live 30-minute sessions as they share their perspectives and facilitate an interactive Q&A

  • Sessions focus on clinical topics such as MOA, Efficacy and Safety, Formulary Updates, Implementation for Hospitals and Clinics, and more
  • Participate in multiple sessions with live Q&A

Come back soon for new sessions in 2024!

Clinic, institution, and hospital-based experts will focus on key topics:

Discover Mechanism of Action

Pivotal Trials: Exploring Efficacy & Safety

Adding a New Product Into Your Formulary

Activating Simple Implementation for Hospitals and Clinics


Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Important safety information


Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions

  • Hypersensitivity Including Anaphylaxis: Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human IgG1 monoclonal antibodies. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy.
  • Use in Individuals with Clinically Significant Bleeding Disorders: As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.